Huakang Biomedical Holdings Company Limited provided unaudited consolidated earnings guidance for the three months ended March 31, 2021. For the three months, the company expected to record a loss attributable to owners of the Company of approximately RMB 1.1 million for the three months ended 31 March 2021 (the "Current Period"), representing a significant decrease in loss of approximately RMB 1.7 million comparing with the three months ended 31 March 2020 (the "Corresponding Period ") of a loss attributable to owners of the Company of approximately RMB 2.8 million. The Board believes that the estimated significant decrease in loss in the Current Period was mainly attributable to (i) a significant increase in the Group's revenue of approximately RMB 2.8 million; and (ii) during the Corresponding Period, there were more than five weeks' sales and productions halt of the Group's factory in the People's Republic of China as a result of the outbreak of the novel coronavirus (COVID-19) epidemic whereas during the Current Period, there was no such impact.